1
00:00:00,080 --> 00:00:03,640
Speaker 1: On the beginning during an end of COVID Moderni's CEO

2
00:00:04,280 --> 00:00:08,760
Speaker 1: Stefan Banzel gave us great, great leadership. We know that

3
00:00:08,880 --> 00:00:14,360
Speaker 1: is an incredible program the University of Minnesota Biological Engineering. Stefan,

4
00:00:14,440 --> 00:00:16,520
Speaker 1: I want to go to one of the great people

5
00:00:16,560 --> 00:00:20,800
Speaker 1: we lost this year, which was a singer songwriter, Jimmy Buffett.

6
00:00:21,239 --> 00:00:23,800
Speaker 1: He died a skin cancer. What are you going to

7
00:00:23,880 --> 00:00:28,520
Speaker 1: do about skin cancer? Every listener, every viewer, it's an

8
00:00:28,560 --> 00:00:29,560
Speaker 1: unspoken fear.

9
00:00:31,120 --> 00:00:34,120
Speaker 2: Well, good morning, and thank you for having me today.

10
00:00:34,280 --> 00:00:37,760
Speaker 2: And you're right. Today is a huge day of hope

11
00:00:38,080 --> 00:00:42,080
Speaker 2: for cancer patient in generl and for melanoma patient first.

12
00:00:42,600 --> 00:00:45,440
Speaker 2: Skin cancer is a scary thing. And what we are

13
00:00:45,440 --> 00:00:50,640
Speaker 2: doing at Moderonna is wh're using our technology to develop

14
00:00:50,920 --> 00:00:55,400
Speaker 2: individualized treatment where we make a different chemical drug for

15
00:00:55,560 --> 00:00:59,600
Speaker 2: different patients. Everybody gets a different drug customized to the

16
00:00:59,680 --> 00:01:01,360
Speaker 2: DNA of VA cancer cell.

17
00:01:01,440 --> 00:01:02,720
Speaker 3: And the data are striking.

18
00:01:03,480 --> 00:01:06,480
Speaker 2: We compared our drug to the best drug available to

19
00:01:06,560 --> 00:01:11,160
Speaker 2: the keythedra from mark, a checkpoint inhibitor, and the two

20
00:01:11,240 --> 00:01:15,040
Speaker 2: year data that we shared a year ago showed forty

21
00:01:15,080 --> 00:01:20,800
Speaker 2: four percent improvement of free survival of people on this Today.

22
00:01:20,800 --> 00:01:23,319
Speaker 2: We don't seeing the three year survival is now at

23
00:01:23,400 --> 00:01:26,280
Speaker 2: forty nine percent. It's already one in two people if

24
00:01:26,319 --> 00:01:29,360
Speaker 2: you think about it, that are surviving as us the

25
00:01:29,400 --> 00:01:33,360
Speaker 2: best drug available today to the right. We still have

26
00:01:33,360 --> 00:01:37,319
Speaker 2: a lot of ideas scientifically manufacturing wise on how we

27
00:01:37,360 --> 00:01:39,800
Speaker 2: think we can even improve that, and so we are

28
00:01:39,880 --> 00:01:43,480
Speaker 2: rushing this into a phase three. The phase three is

29
00:01:43,520 --> 00:01:46,720
Speaker 2: recruiting very quickly, but we're also at the same time

30
00:01:46,760 --> 00:01:50,000
Speaker 2: because the data is so strong. You know, there's around

31
00:01:50,000 --> 00:01:52,720
Speaker 2: three thousand people who died of skin can supper year

32
00:01:52,760 --> 00:01:56,960
Speaker 2: around the world. We're also wanting to talk to regulators

33
00:01:57,000 --> 00:02:01,840
Speaker 2: to see eaither path for accelerated proboard because the safety

34
00:02:01,840 --> 00:02:05,560
Speaker 2: profile of toxicity is very similar to that drug kit

35
00:02:05,640 --> 00:02:08,640
Speaker 2: you drive along, and so you have a very interesting

36
00:02:08,960 --> 00:02:12,520
Speaker 2: risky world opportunity you have for patients which is one

37
00:02:12,600 --> 00:02:15,639
Speaker 2: in two chants to make it with our drug right

38
00:02:15,639 --> 00:02:17,600
Speaker 2: out of three.

39
00:02:18,360 --> 00:02:21,320
Speaker 1: You mentioned Steffan merk Or. I think of Bristol Myers

40
00:02:21,320 --> 00:02:24,560
Speaker 1: in their commitment to cancer therapy is over decades and decades.

41
00:02:24,880 --> 00:02:28,320
Speaker 1: Can you do this by going alone or by definition

42
00:02:28,480 --> 00:02:31,840
Speaker 1: to someone with your huge triumph in COVID, do you

43
00:02:32,000 --> 00:02:35,600
Speaker 1: need to merge in joint venture in some form with

44
00:02:35,680 --> 00:02:37,080
Speaker 1: a bigger platform.

45
00:02:37,800 --> 00:02:39,640
Speaker 3: Yes, actually we are partnered with Merk.

46
00:02:39,840 --> 00:02:42,560
Speaker 2: So what is interesting about this study that we are

47
00:02:42,600 --> 00:02:47,160
Speaker 2: sharing today is we compare two populations. One population gets

48
00:02:47,320 --> 00:02:50,600
Speaker 2: the Merk drug and the ogre propati get the Merk

49
00:02:50,639 --> 00:02:54,200
Speaker 2: drug and as an intramuscill also just injected in your

50
00:02:54,280 --> 00:02:57,600
Speaker 2: arm or product that is customized.

51
00:02:57,000 --> 00:02:58,160
Speaker 3: Individualized for them.

52
00:02:58,200 --> 00:03:00,280
Speaker 2: And that's why you see the big difference of one

53
00:03:00,320 --> 00:03:03,720
Speaker 2: in two people surviving just use the Merk jraugglon. So

54
00:03:03,720 --> 00:03:08,600
Speaker 2: when a partner with Merk commercially clinically some clinical studies,

55
00:03:08,680 --> 00:03:11,679
Speaker 2: modern A team is doing some clinical studies, Milk team

56
00:03:11,760 --> 00:03:14,320
Speaker 2: is doing well. So not on Monday was starting. We

57
00:03:14,400 --> 00:03:16,679
Speaker 2: belong to study. As you know, lung is a big

58
00:03:16,760 --> 00:03:21,560
Speaker 2: killer in cancer. Fortunately we believe that all technology will

59
00:03:21,560 --> 00:03:24,960
Speaker 2: also have big impact on lung cancer. So very excited

60
00:03:25,040 --> 00:03:28,280
Speaker 2: and we are going after many more cancers, starting more studies.

61
00:03:28,600 --> 00:03:30,480
Speaker 3: In twenty twenty four.

62
00:03:30,280 --> 00:03:33,280
Speaker 4: Stephan Moderna got a huge boost from the COVID vaccine.

63
00:03:33,280 --> 00:03:35,400
Speaker 4: We saw that in the share price that it arose

64
00:03:35,440 --> 00:03:39,280
Speaker 4: tremendously and then it struggled last year, shares lower by

65
00:03:39,280 --> 00:03:41,320
Speaker 4: almost thirty percent. This year, the shares a lower by

66
00:03:41,360 --> 00:03:44,360
Speaker 4: fifty six percent. How important is it to you to

67
00:03:44,360 --> 00:03:48,200
Speaker 4: get the cancer vaccine off the ground to offset the

68
00:03:48,320 --> 00:03:50,680
Speaker 4: lack of sales in some of the COVID vaccines that

69
00:03:50,680 --> 00:03:54,000
Speaker 4: we've seen with the latest in particular, Adviser.

70
00:03:55,320 --> 00:03:56,920
Speaker 2: Yeah, So if you think about what happened with the

71
00:03:56,960 --> 00:04:01,080
Speaker 2: company in twenty nineteen, we had no sas, and then

72
00:04:01,120 --> 00:04:02,200
Speaker 2: what happened with COVID.

73
00:04:02,280 --> 00:04:04,800
Speaker 3: We add in twenty one eighteen billion dollar our.

74
00:04:04,800 --> 00:04:07,800
Speaker 2: Sales, which is a lot compared to with and a

75
00:04:07,800 --> 00:04:11,040
Speaker 2: lot of pharmastical companies, and then in twenty twenty one

76
00:04:11,080 --> 00:04:14,320
Speaker 2: when eighteen billion dollar sales. So in twenty way two

77
00:04:14,360 --> 00:04:16,520
Speaker 2: and so if you look at it, we are moving

78
00:04:16,560 --> 00:04:19,960
Speaker 2: into anademic market. As we said in twenty four we

79
00:04:20,000 --> 00:04:21,640
Speaker 2: antipaid at least four.

80
00:04:21,480 --> 00:04:25,400
Speaker 3: Billion dollar sales. We're gaining market share. We're working on

81
00:04:25,400 --> 00:04:26,320
Speaker 3: going the market as well.

82
00:04:26,320 --> 00:04:28,360
Speaker 2: But in the US, if you look at it last year,

83
00:04:28,400 --> 00:04:29,960
Speaker 2: what thirty six percent market share.

84
00:04:30,400 --> 00:04:32,919
Speaker 3: In the last few weeks with fifty two to fifty.

85
00:04:32,600 --> 00:04:35,039
Speaker 2: Three percent market share, we're actually now the leader in

86
00:04:35,080 --> 00:04:37,520
Speaker 2: the US. And if you look in twenty four we're

87
00:04:37,560 --> 00:04:41,039
Speaker 2: launching URSV, which is a big opportunity. If you look

88
00:04:41,040 --> 00:04:44,400
Speaker 2: at what Pfizer and JESK reported in Q three the

89
00:04:44,640 --> 00:04:48,440
Speaker 2: IC market is around two x what analysts expected. So

90
00:04:48,440 --> 00:04:50,560
Speaker 2: it's a great face because we believe we're becoming the

91
00:04:50,560 --> 00:04:53,120
Speaker 2: best product on the market. We have more launches in

92
00:04:53,160 --> 00:04:56,960
Speaker 2: twenty five through full plus Covid combined and they can

93
00:04:57,000 --> 00:04:59,560
Speaker 2: sell as early as twenty five, so we're basically going

94
00:04:59,600 --> 00:05:02,520
Speaker 2: into else growth and the pipe plane is really exciting.

95
00:05:02,800 --> 00:05:05,480
Speaker 2: We have seven program in phase three, so modern it's

96
00:05:05,480 --> 00:05:08,400
Speaker 2: sort a one drug company. It's a platform and there's

97
00:05:08,440 --> 00:05:10,560
Speaker 2: not been platforms before us, so I think a lot

98
00:05:10,560 --> 00:05:12,640
Speaker 2: of people are still getting the head around what does

99
00:05:12,680 --> 00:05:15,040
Speaker 2: it look like. But if you look at the all

100
00:05:15,120 --> 00:05:17,839
Speaker 2: the drugs that are working, we have COVID working and

101
00:05:17,880 --> 00:05:19,720
Speaker 2: then ls BE working in phase three, and then flu

102
00:05:19,760 --> 00:05:22,480
Speaker 2: working in phase three, three out of free product in

103
00:05:22,520 --> 00:05:25,120
Speaker 2: a row with positive phase three. That doesn't happen in

104
00:05:25,160 --> 00:05:29,960
Speaker 2: pharmaceutical companies because we use old analog technology. We're using

105
00:05:30,000 --> 00:05:33,120
Speaker 2: an information technology, and so the pace at which we

106
00:05:33,120 --> 00:05:35,040
Speaker 2: will grow the company I think is going to be

107
00:05:35,120 --> 00:05:35,960
Speaker 2: quite unprecedented.

108
00:05:36,000 --> 00:05:38,279
Speaker 5: Well, let's talk about your sales team. Your chief commercial

109
00:05:38,279 --> 00:05:41,520
Speaker 5: officer is leaving as we understand, what are you planning

110
00:05:41,560 --> 00:05:42,240
Speaker 5: to do differently?

111
00:05:43,320 --> 00:05:45,640
Speaker 2: So actually what we've done is we decided with a

112
00:05:45,720 --> 00:05:48,480
Speaker 2: board and the team to actually take a layer out

113
00:05:49,000 --> 00:05:51,520
Speaker 2: because we said the property for twenty four to twenty

114
00:05:51,520 --> 00:05:55,440
Speaker 2: five is sales, and so now the region's report directly

115
00:05:55,440 --> 00:05:57,680
Speaker 2: into me. I spent the last two days with a

116
00:05:57,760 --> 00:06:01,960
Speaker 2: sales team only sweating what we're doing, detail by detail,

117
00:06:02,360 --> 00:06:06,279
Speaker 2: to grow the market, to gain more market share, and

118
00:06:06,360 --> 00:06:08,599
Speaker 2: to do a superb launch for OURSV.

119
00:06:08,760 --> 00:06:10,479
Speaker 3: I believe with ours you we're the best product.

120
00:06:10,839 --> 00:06:13,160
Speaker 2: The product of our competitors that are being used today

121
00:06:13,200 --> 00:06:17,160
Speaker 2: on the market are very cumbersome for pharmacists to prepare.

122
00:06:17,520 --> 00:06:20,080
Speaker 2: Our product is a profit syringe. We'll be the only

123
00:06:20,120 --> 00:06:22,359
Speaker 2: product in the market. Look at pharmacy retail. We have

124
00:06:22,400 --> 00:06:25,200
Speaker 2: even strikes because it's so hard for people in the

125
00:06:25,200 --> 00:06:28,400
Speaker 2: pharmacy to deal with all the lot of work during

126
00:06:28,440 --> 00:06:30,960
Speaker 2: the full season. So we're just working on all those

127
00:06:30,960 --> 00:06:33,320
Speaker 2: things to make sure we drive sales growth and we

128
00:06:33,360 --> 00:06:34,280
Speaker 2: accelerate ourselves.

129
00:06:34,400 --> 00:06:37,400
Speaker 5: Stephan, I wanted to finish on something quite eloicate. You

130
00:06:37,480 --> 00:06:41,320
Speaker 5: run quite a polarizing company, celebrated in many ways for

131
00:06:41,360 --> 00:06:44,080
Speaker 5: the tremendous innovation, but I think there's always going to

132
00:06:44,120 --> 00:06:48,360
Speaker 5: be a degree of resentment towards companies that benefited from

133
00:06:48,360 --> 00:06:52,039
Speaker 5: the policy that pushed people to take your products. Do

134
00:06:52,080 --> 00:06:54,000
Speaker 5: you think that's something you need to repair.

135
00:06:55,839 --> 00:06:58,560
Speaker 2: Look, there was an enemy, which was a virus, and

136
00:06:58,640 --> 00:07:02,920
Speaker 2: we worked tirelessly, seven days a week to.

137
00:07:02,960 --> 00:07:03,960
Speaker 3: Get the vaccine out.

138
00:07:04,160 --> 00:07:08,400
Speaker 2: It has been shown by several public health analyzes that

139
00:07:08,560 --> 00:07:12,920
Speaker 2: we saved millions of lives around the world. What policy

140
00:07:13,160 --> 00:07:15,680
Speaker 2: officially decided to do in different countries around the world

141
00:07:15,880 --> 00:07:18,560
Speaker 2: was not the company's decision. It was the company's decision

142
00:07:18,640 --> 00:07:21,880
Speaker 2: of governments. Our enemy was the virus. I think we

143
00:07:21,920 --> 00:07:24,760
Speaker 2: had a tremendous impact on lives, helped a lot of people,

144
00:07:25,280 --> 00:07:27,360
Speaker 2: help all of us to go back into the real

145
00:07:27,400 --> 00:07:30,280
Speaker 2: world in terms of kids going back to school, not

146
00:07:30,400 --> 00:07:33,920
Speaker 2: worrying about parents, not worrying about friends that have diseases.

147
00:07:34,320 --> 00:07:36,360
Speaker 2: We are now working on cancer and other things and

148
00:07:36,480 --> 00:07:37,520
Speaker 2: what this company is about.

149
00:07:38,160 --> 00:07:40,640
Speaker 5: Stephan, appreciate your update and looking forward to more the

150
00:07:40,680 --> 00:07:43,240
Speaker 5: same in the year to count. Stephan Panser there of

151
00:07:43,320 --> 00:07:43,880
Speaker 5: maternity